Product Code: BHD0814SB
“Global Digital Biomarkers Market to Reach $16,174.0 Million by 2028.”
Market Report Coverage - Digital Biomarkers
Market Segmentation
- System Components - Data Collection Tools (Wearable Devices, Implantables, and Mobile Applications) and Data Integration Software
- Type - Clinical Trials and Clinical Settings
- Application - Gastrointestinal Diseases, Sleep and Movement Disorders, Cardiovascular, Psychiatric Disorders (Mood and Behavior), Chronic Pain, Neurodegenerative Diseases, Diabetes, Respiratory Diseases, and Others
- End User - Biopharmaceutical Companies, Providers, and Payers
Regional Segmentation
- North America - U.S. and Canada
- Europe - Germany, U.K., France, Italy, Spain, Russia, Netherlands, and Rest-of-Europe
- Asia-Pacific - Japan, China, South Korea, India, Australia and Singapore, and Rest-of-Asia-Pacific
- Latin America - Brazil, Mexico and Rest-of-Latin America
- Rest-of-the-World - Saudi Arabia, U.A.E, Israel, South Africa and Rest-of-Rest-of-the-World
Market Growth Drivers
- Rising Popularity of Digital Biomarkers in Drug Development
- Rising Employment of Vocal Digital Biomarkers
- Rising Use of Wearable Devices and Increasing Smartphone Penetration
- Regulatory Flexibility toward Digital Health Solutions
- Failure of Drugs for Neurodegenerative Disorders
Market Challenges
- Need for Standardized and Interoperable Solutions
- Inaccuracy in Data Measurements
- Lack of Integration and Interoperability between Medical Records and User Generated Data
- Lack of Use Cases of the Return on Investment (ROI) Analysis
Market Opportunities
- Digital Biomarkers: The Future of Precision Medicine
- Early Detection of Neurological Disorders Using Digital Biomarkers
- Increasing Awareness for General Health Management
- Upsurge in Demand of Metabolic, Cardiovascular, and Gastrointestinal Healthcare
- Penetration of Digital Biomarkers in Female, Maternal, Pre- and Neo-Natal Care
- Rise in Usage of Digital Biomarkers to Assess Pulmonary Health
Key Companies Profiled
Alphabet Inc., AliveCor Inc., Akili Interactive Labs, Inc., Cambridge Cognition Ltd, Dassault Systemes, IXICO plc, Koninklijke Philips N.V., Shimmer, Quanterix Corporation, Altoida AG, Evidation Health, Inc., Happify, Inc., Huma, Human API, Mindstrong Health, Neurotrack Technologies, Inc., Orikami, Winterlight Labs Inc.
How This Report Can Add Value
Assuming that the reader is a manufacturer of digital biomarkers, the report will assist them in the following ways:
- Understand their position compared to other key players in the market
- Stay updated with novel technology integration, features, and the latest developments in the market
- Understand the impact of COVID-19 on digital biomarkers and the entry barriers for new companies
- Gain insights into end-user perception concerning the digital biomarkers market
- Identify some key players in the market and understand their valuable contribution
Key Questions Answered in the Report:
- How has COVID-19 impacted the growth of the global digital biomarkers market?
- What are the key regulations governing the digital biomarkers market in key regions?
- What technological developments are projected to have the maximum influence on the global digital biomarkers market?
- Who are the leading players holding significant dominance in the global digital biomarkers market?
- What are some of the growth opportunities which market players can capitalize on?
- What are the drivers and restraints for the global digital biomarkers market?
- Which region has the highest growth rate in the digital biomarkers market?
- Which are the fastest growing countries in terms of the global digital biomarkers market?
- What are the key strategies being adopted by market players in the global digital biomarkers market?
Global Digital Biomarkers Market: Overview
The global digital biomarkers market is projected to witness significant growth during the forecast period 2022-2028. The high prevalence and growing incidences of chronic diseases and the technological advancements in digital healthcare systems are the key propellers for the growth of the market.
During the COVID-19 pandemic, technological advancements such as the integration of software and artificial intelligence (AI) in wearable devices, rising adoption of mHealth applications, and growing interest in telemedicine and remote patient monitoring systems have all contributed to the market growth for digital biomarkers. The global digital biomarkers market report highlights that the market was valued at $1,808.3 million in 2021 and is expected to reach $16,174.0 million by 2028. The market is expected to grow at a CAGR of 36.06% during the forecast period 2022-2028.
Global Digital Biomarkers Market Drivers
Conventional chronic disease diagnostics are very subjective and based on a series of visits. As a result, drug development decisions are based on limited, subjective evidence, resulting in large-scale Phase 3 trials of medications that were unsuccessful. Digital biomarkers can predict the efficacy of a drug more swiftly than a conventional clinical endpoint, thereby accelerating product development in the case of certain therapeutic areas. Moreover, the advancements in digital biomarker technology such as voice-based digital biomarkers, mHealth applications, and the adoption of smart wearable devices are gaining popularity among people.
Furthermore, with the rise in prevalence and incidence of chronic diseases, technological adoption will also increase. As a result, disease diagnosis will become more prevalent, and the global market for digital biomarkers will expand. Governments invest a significant amount of money in healthcare insurance so that the overall healthcare costs can be reduced, and the quality of life and affordability of the treatment can be enhanced.
Global Digital Biomarkers Market Restraints
The factors restraining the growth of the global digital biomarkers devices market include the risks associated with return on investment (RoI) and the lack of standardized and interoperability solutions. Moreover, people are specifically concerned about the increased risk of medical errors and invasion of patients' privacy when digital health devices are being used instead of conventional methods.
Global Digital Biomarkers Market Opportunities
High growth opportunities in emerging economies and the emergence of local companies in Asia-Pacific and the Middle East and Africa hold immense potential for digital biomarkers market growth. In an era of machine learning (ML) and artificial intelligence (AI), extracting quantitative digital biomarkers that help in illness detection, characterization, monitoring, and therapy response assessment is becoming increasingly desirable.
Impact of COVID-19 on the Global Digital Biomarkers Market
The COVID-19 pandemic had a debilitating impact on the global healthcare ecosystem. Hospitals and clinics faced several challenges, such as lack of resources, high patient influx, and risk of infection among care providers. The market is projected to witness considerable growth during the forecast period 2022-2028. The increasing innovations and product designs in the global market and the growing use in emerging economies are the driving factors for the market's growth.
Market Segmentation
Global Digital Biomarkers Market (by System Components)
The global digital biomarkers market based on system components product type has been segmented into data collection tools and data integration software. Data collection tools have been further segmented into wearables, implantables, and mobile applications.
Global Digital Biomarkers Market (by Type)
The global digital biomarkers market based on product type has been segmented into clinical trials and clinical settings.
Global Digital Biomarkers Market (by Application)
The global digital biomarkers market, based on application, has been segmented into gastrointestinal diseases, sleep and movement disorders, cardiovascular, psychiatric disorders (mood and behavior), neurodegenerative diseases, diabetes, respiratory diseases, and others.
Global Digital Biomarkers Market (by End User)
The global digital biomarkers market based on end user has been segmented into biopharmaceutical companies, providers, and payers.
Global Digital Biomarkers Market (by Region)
The different regions covered under the global digital biomarkers market include North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World.
North America is expected to be the most lucrative region for the global digital biomarkers market due to advanced healthcare infrastructure and a high focus on research and development activities. The Asia-Pacific digital biomarkers market is one of the profitable markets with immense potential for expansion by key players in the global digital biomarkers market. The Asia-Pacific digital biomarkers market is expected to grow at the fastest rate during the forecast period. This can be attributed to the massive geriatric population base, which is driving the increase in the volume of digital biomarkers.
Key Market Players and Competition Synopsis
Some key players operating in the market include: AliveCor, Inc., Pear Therapeutics Inc., Abbott, Akili Interactive Labs, Inc., Koninklijke Phillips N.V., Huma, Koneksa Health, Alphabet Inc., and Neurotrack Technologies, Inc.
Some strategies covered in this segment are funding activities, mergers and acquisitions, partnerships, alliances, business expansions, regulatory and legal activities, and new offerings and upgradations.
Table of Contents
1 Markets
- 1.1 Market Outlook
- 1.1.1 Product Definition
- 1.1.1.1 Data Collection Tools
- 1.1.1.1.1 Wearable Devices
- 1.1.1.1.2 Implantables
- 1.1.1.1.3 Mobile Applications
- 1.1.1.2 Data Integration Software
- 1.1.2 Inclusion and Exclusion Criteria
- 1.1.3 Key Findings
- 1.1.4 Global Market Scenario
- 1.1.4.1 Realistic Growth Scenario
- 1.1.4.2 Optimistic Growth Scenario
- 1.1.4.3 Pessimistic/Conservative Growth Scenario
- 1.2 Global Digital Biomarkers Market Overview
- 1.2.1 Current State of Digital Biomarker
- 1.2.2 Types of Biomarkers
- 1.2.2.1 Wellness
- 1.2.2.2 Disease
- 1.2.2.3 Drugs
- 1.2.3 Industry
- 1.2.3.1 Pharmaceutical
- 1.2.3.2 Biotechnology/Life Sciences
- 1.2.3.3 Medical Devices
- 1.2.3.4 Application Vendors
- 1.2.4 Clinical Trials (Clinical Research Organization)
- 1.2.4.1 Technology Vendors
- 1.2.5 Digital Biomarker Ecosystem
- 1.2.5.1 Wearable Devices
- 1.2.5.2 Implantable Components/ Sensors
- 1.2.5.3 Ocular Devices
- 1.2.5.4 Accelerometers
- 1.2.5.5 Smart Home Systems/IoTs
- 1.2.5.6 AR/VR Platforms
- 1.2.5.7 Desktop/Web Applications
- 1.2.6 Data Measurement
- 1.2.6.1 Physiological Parameters
- 1.2.6.2 Behavioral Parameters
- 1.3 Industry Outlook
- 1.3.1 Technology Landscape
- 1.3.1.1 Artificial Intelligence and Machine Learning
- 1.3.1.2 Augmented Reality (AR) and Virtual Reality (VR)
- 1.3.1.3 Blockchain
- 1.3.1.4 Edge Computing
- 1.3.1.5 Cloud Computing
- 1.3.2 Key Trends
- 1.3.3 Opportunity Assessment
- 1.3.3.1 Short-Term Growth Potential
- 1.3.3.2 Long-Term Growth Potential
- 1.3.4 Product Benchmarking
- 1.3.5 Patent Analysis
- 1.3.5.1 Awaited Technological Developments
- 1.3.5.2 Patent Publication Growth Trend
- 1.3.5.3 Patent Analysis (by Country/Cluster)
- 1.3.6 Case Studies: Key Therapeutic Areas
- 1.3.6.1 Cardiovascular Diseases
- 1.3.6.2 Parkinson's Diseases
- 1.3.6.3 Alzheimer's Diseases
- 1.4 Impact of COVID-19
- 1.4.1 Impact on Digital Biomarkers
- 1.4.2 Impact on Device Adoption
- 1.4.3 Impact on Market Size
- 1.4.3.1 Pre-COVID-19 Phase
- 1.4.3.1.1 Global and Regional Analysis
- 1.4.3.2 During COVID-19 Phase
- 1.4.3.2.1 Global and Regional Analysis
- 1.4.3.3 Post-COVID-19 Phase
- 1.5 Business Dynamics
- 1.5.1 Impact Analysis
- 1.5.2 Business Drivers
- 1.5.2.1 Rising Popularity of Digital Biomarkers in Drug Development
- 1.5.2.2 Rising Employment of Vocal Digital Biomarkers
- 1.5.2.3 Rising Use of Wearable Devices and Increasing Smartphone Penetration
- 1.5.2.4 Regulatory Flexibility toward Digital Health Solutions
- 1.5.2.5 Failure of Drugs for Neurodegenerative Disorders
- 1.5.3 Business Challenges
- 1.5.3.1 Need for Standardized and Interoperable Solutions
- 1.5.3.2 Inaccuracy in Data Measurements
- 1.5.3.3 Lack of Integration and Interoperability between Medical Records and User Generated Data
- 1.5.3.4 Lack of Use Cases of the Return on Investment (ROI) Analysis
- 1.5.4 Business Opportunities
- 1.5.4.1 Digital Biomarkers: The Future of Precision Medicine
- 1.5.4.2 Early Detection of Neurological Disorders Using Digital Biomarkers
- 1.5.4.3 Increasing Awareness for General Health Management
- 1.5.4.4 Upsurge in Demand of Metabolic, Cardiovascular, and Gastrointestinal Healthcare
- 1.5.4.5 Penetration of Digital Biomarkers in Female, Maternal, Pre- and Neo-Natal Care
- 1.5.4.6 Rise in Usage of Digital Biomarkers to Assess Pulmonary Health
2 Global Digital Biomarker Market (by Application)
- 2.1 Opportunity Assessment
- 2.2 Growth-Share Matrix
- 2.3 Gastrointestinal Diseases
- 2.4 Sleep and Movement Disorders
- 2.5 Cardiovascular
- 2.6 Psychiatric Disorders (Mood and Behavior)
- 2.7 Chronic Pain
- 2.8 Neurodegenerative Diseases
- 2.9 Diabetes
- 2.1 Respiratory Diseases
- 2.11 Others
3 Global Digital Biomarkers Market (by End User)
- 3.1 Opportunity Assessment
- 3.2 Growth-Share Matrix
- 3.3 Biopharmaceutical Companies
- 3.4 Payers
- 3.5 Providers
4 Global Digital Biomarkers Market (by System Components)
- 4.1 Opportunity Assessment
- 4.2 Market Share Analysis
- 4.3 Growth-Share Matrix
- 4.4 Data Collection Tools
- 4.4.1 Wearables Devices
- 4.4.1.1 Evolution of Wearable Devices in Clinical Trials
- 4.4.1.2 Wearable Devices in Clinical Trials
- 4.4.1.3 Actigraphy Devices
- 4.4.1.4 Opportunity in Digital Biomarker
- 4.4.1.5 New Developments
- 4.4.1.6 Market Estimation and Forecast
- 4.4.2 Implantables
- 4.4.2.1 Opportunity in Digital Biomarker
- 4.4.2.2 New Developments
- 4.4.2.3 Market Estimation and Forecast
- 4.4.3 Mobile Applications
- 4.4.3.1 Opportunity in Digital Biomarkers
- 4.4.3.2 New Developments
- 4.4.3.3 Market Estimation and Forecast
- 4.5 Data Integration Software
- 4.5.1 Opportunity in Digital Biomarker
- 4.5.2 New Developments
- 4.5.3 Market Estimation and Forecast
5 Global Digital Biomarkers Market (by Type)
- 5.1 Opportunity Assessment
- 5.2 Market Share Analysis
- 5.3 Growth-Share Matrix
- 5.4 Clinical Trials
- 5.5 Clinical Settings
6 Region
- 6.1 North America Digital Biomarkers Market
- 6.1.1 Regulatory Framework
- 6.1.2 Opportunity Assessment
- 6.1.3 Market Dynamics
- 6.1.4 Sizing and Forecast Analysis
- 6.1.4.1 North America Digital Biomarkers Market (by Application)
- 6.1.4.2 North America Digital Biomarkers Market (by Type)
- 6.1.5 North America Digital Biomarkers Market (by Country)
- 6.1.5.1 U.S.
- 6.1.5.1.1 Digital Health Scenario
- 6.1.5.1.2 Degree of Adoption of Wearables
- 6.1.5.1.3 Degree of Adoption of Mobile Health Applications
- 6.1.5.1.4 Local Players in the Digital Biomarker Market
- 6.1.5.1.5 U.S. Digital Biomarkers Market
- 6.1.5.1.6 U.S. Digital Biomarkers Market (by Type)
- 6.1.5.1.7 U.S. Digital Biomarkers Market (by Application)
- 6.1.5.2 Canada
- 6.1.5.2.1 Digital Health Scenario
- 6.1.5.2.2 Degree of Adoption of Wearables
- 6.1.5.2.3 Degree of Adoption of Mobile Health Applications
- 6.1.5.2.4 Local Players in the Digital Biomarker Market
- 6.1.5.2.5 Canada Digital Biomarkers Market
- 6.1.5.2.6 Canada Digital Biomarkers Market (by Type)
- 6.1.5.2.7 Canada Digital Biomarkers Market (by Application)
- 6.2 Europe Digital Biomarkers Market
- 6.2.1 Regulatory Framework
- 6.2.2 Opportunity Assessment
- 6.2.3 Market Dynamics
- 6.2.4 Sizing and Forecast Analysis
- 6.2.4.1 Europe Digital Biomarkers Market (by Application)
- 6.2.4.2 Europe Digital Biomarkers Market (by Type)
- 6.2.5 Europe Digital Biomarkers Market (by Country)
- 6.2.5.1 Netherlands
- 6.2.5.1.1 Digital Health Scenario
- 6.2.5.1.2 Degree of Adoption of Wearables
- 6.2.5.1.3 Degree of Adoption of Mobile Health Applications
- 6.2.5.1.4 Local Players in the Digital Biomarker Market
- 6.2.5.1.5 Netherlands Digital Biomarkers Market
- 6.2.5.1.6 Netherlands Digital Biomarkers Market (by Type)
- 6.2.5.1.7 Netherlands Digital Biomarkers Market (by Application)
- 6.2.5.2 Germany
- 6.2.5.2.1 Digital Health Scenario
- 6.2.5.2.2 Degree of Adoption of Wearables
- 6.2.5.2.3 Reluctance to Fitness Trackers
- 6.2.5.2.4 Future of Digital Health in Germany
- 6.2.5.2.5 Germany Digital Biomarkers Market
- 6.2.5.2.6 Germany Digital Biomarkers Market (by Type)
- 6.2.5.2.7 Germany Digital Biomarkers Market (by Application)
- 6.2.5.3 France
- 6.2.5.3.1 Digital Health Scenario
- 6.2.5.3.2 Degree of Adoption of Wearables
- 6.2.5.3.3 Local Players in Digital Biomarkers Market
- 6.2.5.3.4 France Digital Biomarkers Market
- 6.2.5.3.5 France Digital Biomarkers Market (by Type)
- 6.2.5.3.6 France Digital Biomarkers Market (by Application)
- 6.2.5.4 Italy
- 6.2.5.4.1 Digital Health Scenario
- 6.2.5.4.2 Degree of Adoption of Wearables
- 6.2.5.4.3 Italy Digital Biomarkers Market
- 6.2.5.4.4 Italy Digital Biomarkers Market (by Type)
- 6.2.5.4.5 Italy Digital Biomarkers Market (by Application)
- 6.2.5.5 Spain
- 6.2.5.5.1 Digital Health Scenario
- 6.2.5.5.2 Degree of Adoption of Wearables
- 6.2.5.5.3 Spain Digital Biomarkers Market
- 6.2.5.5.4 Spain Digital Biomarkers Market (by Type)
- 6.2.5.5.5 Spain Digital Biomarkers Market (by Application)
- 6.2.5.6 Russia
- 6.2.5.6.1 Digital Health Scenario
- 6.2.5.6.2 Degree of Adoption of Wearables
- 6.2.5.6.3 Degree of Adoption of Mobile Health Applications
- 6.2.5.6.4 Russia Digital Biomarkers Market
- 6.2.5.6.5 Russia Digital Biomarkers Market (by Type)
- 6.2.5.6.6 Russia Digital Biomarkers Market (by Application)
- 6.2.5.7 U.K.
- 6.2.5.7.1 Digital Health Scenario
- 6.2.5.7.2 Degree of Adoption of Wearables
- 6.2.5.7.3 Increasing Sales of Smartwatches
- 6.2.5.7.4 Abandonment of Wearables
- 6.2.5.7.5 Local Players in Digital Biomarkers
- 6.2.5.7.6 U.K. Digital Biomarkers Market
- 6.2.5.7.7 U.K. Digital Biomarkers Market (by Type)
- 6.2.5.7.8 U.K. Digital Biomarkers Market (by Application)
- 6.2.5.8 Rest-of-Europe
- 6.2.5.8.1 Digital Health Scenario
- 6.2.5.8.2 Degree of Adoption of Wearables
- 6.2.5.8.3 Increasing Sales of Smartwatches
- 6.2.5.8.4 Local Players in Digital Biomarkers
- 6.2.5.8.5 Rest-of-Europe Digital Biomarkers Market
- 6.2.5.8.6 Rest-of-Europe Digital Biomarkers Market (by Type)
- 6.2.5.8.7 Rest-of-Europe Digital Biomarkers Market (by Application)
- 6.3 Asia-Pacific Digital Biomarkers Market
- 6.3.1 Regulatory Framework
- 6.3.2 Opportunity Assessment
- 6.3.3 Market Dynamics
- 6.3.4 Sizing and Forecast Analysis
- 6.3.4.1 Asia-Pacific Digital Biomarkers Market (by Application)
- 6.3.4.2 Asia-Pacific Digital Biomarkers Market (by Type)
- 6.3.5 Asia-Pacific Digital Biomarkers Market (by Country)
- 6.3.5.1 Singapore
- 6.3.5.1.1 Digital Health Scenario
- 6.3.5.1.2 Degree of Adoption of Wearables
- 6.3.5.1.3 Degree of Adoption of Mobile Health
- 6.3.5.1.4 Singapore Digital Biomarkers Market
- 6.3.5.1.5 Singapore Digital Biomarkers Market (by Type)
- 6.3.5.1.6 Singapore Digital Biomarkers Market (by Application)
- 6.3.5.2 Australia
- 6.3.5.2.1 Digital Health Scenario
- 6.3.5.2.2 Degree of Adoption of Wearables
- 6.3.5.2.3 Degree of Adoption of Mobile Health
- 6.3.5.2.4 Australia Digital Biomarkers Market
- 6.3.5.2.5 Australia Digital Biomarkers Market (by Type)
- 6.3.5.2.6 Australia Digital Biomarkers Market (by Application)
- 6.3.5.3 India
- 6.3.5.3.1 Digital Health Scenario
- 6.3.5.3.2 Degree of Adoption of Wearables
- 6.3.5.3.3 Degree of Adoption of Mobile Health
- 6.3.5.3.4 India Digital Biomarkers Market
- 6.3.5.3.5 India Digital Biomarkers Market (by Type)
- 6.3.5.3.6 India Digital Biomarkers Market (by Application)
- 6.3.5.4 South Korea
- 6.3.5.4.1 Digital Health Scenario
- 6.3.5.4.2 Degree of Adoption of Wearables
- 6.3.5.4.3 Degree of Adoption of Mobile Health
- 6.3.5.4.4 South Korea Digital Biomarkers Market
- 6.3.5.4.5 South Korea Digital Biomarkers Market (by Type)
- 6.3.5.4.6 South Korea Digital Biomarkers Market (by Application)
- 6.3.5.5 Japan
- 6.3.5.5.1 Digital Health Scenario
- 6.3.5.5.2 Degree of Adoption of Wearables
- 6.3.5.5.3 Degree of Adoption of Mobile Health
- 6.3.5.5.4 Japan Digital Biomarkers Market
- 6.3.5.5.5 Japan Digital Biomarkers Market (by Type)
- 6.3.5.5.6 Japan Digital Biomarkers Market (by Application)
- 6.3.5.6 China
- 6.3.5.6.1 Digital Health Scenario
- 6.3.5.6.2 Degree of Adoption of Wearables
- 6.3.5.6.3 Degree of Adoption of Mobile Health
- 6.3.5.6.4 Local Players in Digital Biomarker Market
- 6.3.5.6.5 China Digital Biomarkers Market
- 6.3.5.6.6 China Digital Biomarkers Market (by Type)
- 6.3.5.6.7 China Digital Biomarkers Market (by Application)
- 6.3.5.7 Rest-of-Asia-Pacific
- 6.3.5.7.1 Digital Health Scenario
- 6.3.5.7.2 Degree of Adoption of Wearables
- 6.3.5.7.3 Degree of Adoption of Mobile Health Applications
- 6.3.5.7.4 Rest-of-Asia-Pacific Digital Biomarkers Market
- 6.3.5.7.5 Rest-of-Asia-Pacific Digital Biomarkers Market (by Type)
- 6.3.5.7.6 Rest-of-Asia-Pacific Digital Biomarkers Market (by Application)
- 6.4 Latin America Digital Biomarkers Market
- 6.4.1 Regulatory Framework
- 6.4.2 Opportunity Assessment
- 6.4.3 Market Dynamics
- 6.4.4 Sizing and Forecast Analysis
- 6.4.4.1 Latin America Digital Biomarkers Market (by Application)
- 6.4.4.2 Latin America Digital Biomarkers Market (by Type)
- 6.4.5 Latin America Digital Biomarkers Market (by Country)
- 6.4.5.1 Brazil
- 6.4.5.1.1 Digital Health Scenario
- 6.4.5.1.2 Degree of Adoption of Mobile Health Applications
- 6.4.5.1.3 Brazil Digital Biomarkers Market
- 6.4.5.1.4 Brazil Digital Biomarkers Market (by Type)
- 6.4.5.1.5 Brazil Digital Biomarkers Market (by Application)
- 6.4.5.2 Mexico
- 6.4.5.2.1 Digital Health Scenario
- 6.4.5.2.2 Degree of Adoption of Mobile Health Applications
- 6.4.5.2.3 Mexico Digital Biomarkers Market
- 6.4.5.2.4 Mexico Digital Biomarkers Market (by Type)
- 6.4.5.2.5 Mexico Digital Biomarkers Market (by Application)
- 6.4.5.3 Rest-of-Latin America
- 6.4.5.3.1 Digital Health Scenario
- 6.4.5.3.2 Degree of Adoption of Wearables
- 6.4.5.3.3 Degree of Adoption of Mobile Health
- 6.4.5.3.4 Rest-of-Latin America Digital Biomarkers Market
- 6.4.5.3.5 Rest-of-Latin America Digital Biomarkers Market (by Type)
- 6.4.5.3.6 Rest-of-Latin America Digital Biomarkers Market (by Application)
- 6.5 Rest-of-the-World
- 6.5.1 Regulatory Framework
- 6.5.2 Opportunity Assessment
- 6.5.3 Market Dynamics
- 6.5.4 Sizing and Forecast Analysis
- 6.5.4.1 Rest-of-the-World Digital Biomarkers Market (by Application)
- 6.5.4.2 Rest-of-the-World Digital Biomarkers Market (by Type)
- 6.5.5 Rest-of-the-World Digital Biomarkers Market (by Country)
- 6.5.5.1 Saudi Arabia
- 6.5.5.1.1 Digital Health Scenario
- 6.5.5.1.2 Degree of Adoption of Wearables
- 6.5.5.1.3 Degree of Adoption of Mobile Health Applications
- 6.5.5.1.4 Saudi Arabia Digital Biomarkers Market
- 6.5.5.1.5 Saudi Arabia Digital Biomarkers Market (by Type)
- 6.5.5.1.6 Saudi Arabia Digital Biomarkers Market (by Application)
- 6.5.5.2 U.A.E
- 6.5.5.2.1 Digital Health Scenario
- 6.5.5.2.2 Degree of Adoption of Wearables
- 6.5.5.2.3 Degree of Adoption of Mobile Health Applications
- 6.5.5.2.4 U.A.E. Digital Biomarkers Market
- 6.5.5.2.5 U.A.E. Digital Biomarkers Market (by Type)
- 6.5.5.2.6 U.A.E. Digital Biomarkers Market (by Application)
- 6.5.5.3 Israel
- 6.5.5.3.1 Digital Health Scenario
- 6.5.5.3.2 Degree of Adoption of Wearables
- 6.5.5.3.3 Degree of Adoption of Mobile Health Applications
- 6.5.5.3.4 Israel Digital Biomarkers Market
- 6.5.5.3.5 Israel Digital Biomarkers Market (by Type)
- 6.5.5.3.6 Israel Digital Biomarkers Market (by Application)
- 6.5.5.4 South Africa
- 6.5.5.4.1 Digital Health Scenario
- 6.5.5.4.2 Degree of Adoption of Wearables
- 6.5.5.4.3 Degree of Adoption of Mobile Health Applications
- 6.5.5.4.4 South Africa Digital Biomarkers Market
- 6.5.5.4.5 South Africa Digital Biomarkers Market (by Type)
- 6.5.5.4.6 South Africa Digital Biomarkers Market (by Application)
- 6.5.5.5 Rest-of-Rest-of-the-World
- 6.5.5.5.1 Digital Health Scenario
- 6.5.5.5.2 Degree of Adoption of Wearables
- 6.5.5.5.3 Degree of Adoption of Mobile Health Applications
- 6.5.5.5.4 Rest-of-Rest-of -the-World Digital Biomarkers Market
- 6.5.5.5.5 Rest-of-Rest-of-the-World Digital Biomarkers Market (by Type)
- 6.5.5.5.6 Rest-of-Rest-of-the-World Digital Biomarkers Market (by Application)
7 Market- Company Profiles and Competitive Benchmarking
- 7.1 Competitive Landscape
- 7.1.1 Key Strategies and Developments
- 7.1.1.1 Partnerships, Alliances, and Business Expansions
- 7.1.1.2 Funding Activities
- 7.1.1.2.1 New Offerings
- 7.1.1.2.2 Mergers and Acquisitions
- 7.1.1.2.3 Regulatory and Legal Activities
- 7.2 Company Profiles
- 7.2.1 Established Companies
- 7.2.1.1 Alphabet Inc.
- 7.2.1.1.1 Company Overview
- 7.2.1.1.2 Role of Alphabet Inc. in the Global Digital Biomarkers Market
- 7.2.1.1.3 Product Portfolio and Offerings
- 7.2.1.1.4 Financials
- 7.2.1.1.4.1 Recent Developments
- 7.2.1.1.5 SWOT Analysis
- 7.2.1.2 AliveCor Inc.
- 7.2.1.2.1 Company Overview
- 7.2.1.2.2 Role of AliveCor, Inc. in the Global Digital Biomarkers Market
- 7.2.1.2.3 Product Portfolio and Offerings
- 7.2.1.2.4 Recent Development
- 7.2.1.2.5 SWOT Analysis
- 7.2.1.3 Akili Interactive Labs, Inc.
- 7.2.1.3.1 Company Overview
- 7.2.1.3.2 Role of Akili Interactive Labs in the Global Digital Biomarkers Market
- 7.2.1.3.3 Product Portfolio and Offerings
- 7.2.1.3.3.1.1 Recent Developments
- 7.2.1.3.3.1.2 SWOT Analysis
- 7.2.1.4 Cambridge Cognition Ltd
- 7.2.1.4.1 Company Overview
- 7.2.1.4.2 Role of Cambridge Cognition Ltd in the Global Digital Biomarkers Market
- 7.2.1.4.3 Product Portfolio and Offerings
- 7.2.1.4.4 Financials
- 7.2.1.4.5 Recent Developments
- 7.2.1.4.6 SWOT Analysis
- 7.2.1.5 Dassault Systemes
- 7.2.1.5.1 Company Overview
- 7.2.1.5.2 Role of Dassault Systemes in the Global Digital Biomarkers Market
- 7.2.1.5.3 Product Portfolio and Offerings
- 7.2.1.5.4 Financials
- 7.2.1.5.5 Recent Developments
- 7.2.1.5.6 SWOT Analysis
- 7.2.1.6 IXICO plc
- 7.2.1.6.1 Company Overview
- 7.2.1.6.2 Role of IXICO plc in the Global Digital Biomarkers Market
- 7.2.1.6.3 Product Portfolio and Offerings
- 7.2.1.6.4 Financials
- 7.2.1.6.5 Recent Developments
- 7.2.1.6.6 SWOT Analysis
- 7.2.1.7 Koninklijke Philips N.V.
- 7.2.1.7.1 Company Overview
- 7.2.1.7.2 Role of Koninklijke Philips N.V. in the Global Digital Biomarkers Market
- 7.2.1.7.3 Product Portfolio and Offerings
- 7.2.1.7.4 Financials
- 7.2.1.7.4.1 Koninklijke Philips N.V.: SWOT Analysis
- 7.2.1.8 Shimmer
- 7.2.1.8.1 Company Overview
- 7.2.1.8.2 Role of Shimmer in the Global Digital Biomarkers Market
- 7.2.1.8.3 Product Portfolio and Offerings
- 7.2.1.8.3.1 Recent Developments
- 7.2.1.8.4 SWOT Analysis
- 7.2.1.9 Quanterix Corporation
- 7.2.1.9.1 Company Overview
- 7.2.1.9.2 Role of Quanterix Corporation in the Global Digital Biomarkers Market
- 7.2.1.9.3 Product Portfolio and Offerings
- 7.2.1.9.4 Financials
- 7.2.1.9.5 Recent Developments
- 7.2.1.9.6 SWOT Analysis
- 7.2.2 Start-Ups
- 7.2.2.1 Altoida AG
- 7.2.2.1.1 Company Overview
- 7.2.2.1.2 Role of Altoida AG in the Global Digital Biomarkers Market
- 7.2.2.1.3 Product Portfolio and Offerings
- 7.2.2.1.4 Recent Developments
- 7.2.2.1.5 SWOT Analysis
- 7.2.2.2 Evidation Health, Inc.
- 7.2.2.2.1 Company Overview
- 7.2.2.2.2 Role of Evidation Health, Inc. in the Global Digital Biomarker Market
- 7.2.2.2.3 Product Portfolio and Offerings
- 7.2.2.2.4 Recent Developments
- 7.2.2.2.5 SWOT Analysis
- 7.2.2.3 Happify, Inc.
- 7.2.2.3.1 Company Overview
- 7.2.2.3.2 Role of Happify, Inc. in the Global Digital Biomarker Market
- 7.2.2.3.3 Product Portfolio and Offerings
- 7.2.2.3.4 Recent Developments
- 7.2.2.3.5 SWOT Analysis
- 7.2.2.4 Huma
- 7.2.2.4.1 Company Overview
- 7.2.2.4.2 Role of Huma in the Global Digital Biomarker Market
- 7.2.2.4.3 Product Portfolio and Offerings
- 7.2.2.4.4 Recent Developments
- 7.2.2.4.5 SWOT Analysis
- 7.2.2.5 Human API
- 7.2.2.5.1 Company Overview
- 7.2.2.5.2 Role of Human API in the Global Digital Biomarkers Market.
- 7.2.2.5.3 Product Portfolio and Offerings
- 7.2.2.5.4 Recent Developments
- 7.2.2.5.5 SWOT Analysis
- 7.2.2.6 Mindstrong Health
- 7.2.2.6.1 Company Overview
- 7.2.2.6.2 Role of Mindstrong Health in the Global Digital Biomarker Market
- 7.2.2.6.3 Product Portfolio and Offerings
- 7.2.2.6.4 Recent Developments
- 7.2.2.6.5 SWOT Analysis
- 7.2.2.7 Neurotrack Technologies, Inc.
- 7.2.2.7.1 Company Overview
- 7.2.2.7.2 Role of Neurotrack Technologies, Inc. in the Global Digital Biomarker Market
- 7.2.2.7.3 Product Portfolio and Offerings
- 7.2.2.7.4 Recent Developments
- 7.2.2.7.5 SWOT Analysis
- 7.2.2.8 Orikami
- 7.2.2.8.1 Company Overview
- 7.2.2.8.2 Role of Orikami in the Global Digital Biomarker Market
- 7.2.2.8.3 Product Portfolio and Offerings
- 7.2.2.8.4 Recent Developments
- 7.2.2.8.5 SWOT Analysis
- 7.2.2.9 Winterlight Labs Inc.
- 7.2.2.9.1 Company Overview
- 7.2.2.9.2 Role of Winterlight Labs, Inc. in the Global Digital Biomarkers Market
- 7.2.2.9.3 Product Portfolio and Offerings
- 7.2.2.9.4 Recent Developments
- 7.2.2.9.5 SWOT Analysis